Page 23 - Lupin

Lupin plans expansion, eyes product purchase in chronic and acute therapy

Chronic therapies refer to drugs for ailments which are chronic in nature such as diabetes, hypertension, etc

Lupin shares fall over 4% after company's Q2 net profit dropped 41.5%

The stock dropped 4.13 per cent to end at Rs 852.20 on the BSE. Intra-day, it declined 4.49 per cent to Rs 849

Lupin to develop Brazil as Latin American manufacturing, export hub

Most neighbouring countries recognise the Brazilian drug regulator's approvals

Lupin receives Europe's positive opinion for antimyotonic agent 'NaMuscla'

The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU), the Mumbai-based firm added

Lupin starts strategic review of Japanese arm, targets higher-growth areas

Japanese subsidiaries of Lupin produce treatments in therapeutic areas, including psychiatry and neurology

Lupin's Nagpur facility gets Establishment Inspection Report from US FDA

Shares of Lupin were today trading at Rs 903 per scrip on BSE, down 0.07 per cent from its previous close

Weak US sales take toll on Lupin Q1 performance, stock slides 4.5%

North America sales fall by a quarter, indicating intense pricing pressures

Pharma major Lupin gets UK health regulator's approval for Goa facility

The unit was inspected by United Kingdom's Medicines and Healthcare products Regulatory Agency in March 2018 and there were no critical or major observations cited

Lupin, Boehringer to co-market two oral anti-diabetic drugs in India

The two drugs, Gibtulio Met and Ajaduo, will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names

Lupin hits over four month high; stock rises 5% in two days

In past one month, Lupin has outperformed the market by surging 23% as compared to 1.4% rise in the S&P BSE Sensex.

Lupin Pharmaceuticals' smooth-run in Japan; all eyes on biosimilars growth

Lupin's Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit

Lupin rises 2% on partnership with Mylan for Enbrel Biosimilar

Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product.

Lupin, Nichi-Iko to commercialise arthritis biosimilar in Japan

Etanercept is used in treatment of auto immune diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis and ankylosing spondylitis

Lupin launches drug to control postpartum hemorrhage after USFDA nod

Lupin's product is the generic equivalent of Novartis Pharmaceuticals Corp's Methergine

Lupin showing signs of revival under its second-generation leadership team

But the going is still tricky

Lupin gains on EIR from USFDA for Pithampur Unit 1

At 10:41 am; the stock was trading 3% higher at Rs 808 after rallied 7% to Rs 843 on the NSE in intra-day trade

Lupin extends gain as UK MHRA completes inspection at Goa unit

The stock was up 3% to Rs 798, extending its Monday's 5% surge on the BSE

Lupin stock in 2017 global worst-performer list, says Evaluate report

US Food and Drug Administration's warning letters to two Lupin plants in Goa and Indore in November was the main reason for the decline in the stock price

Lupin hits 52-week low on weak Q3 results

The stock hit 52-week low of Rs 782, down 2.5% in intra-day trade, extending its previous day's 6% decline on BSE

Lupin: Q3 shows further rise in US pricing pressure as net profit falls 65%

Gross profit margins fell to a 16-quarter low, pulling down earnings by 65% y-o-y